ArticleNature cancer2021
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06855810 (Chinese Children's Cancer Group T-cell Acute Lymphoblastic Leukemia -2025 Project), which is not on this map. Cited by 85 papers.
0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed
28.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06855810 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation
Chinese Children's Cancer Group T-cell Acute Lymphoblastic Leukemia -2025 Project
Who cites it
85 citing papers in PubMed, 151 citations in OpenAlex.
- Understanding and clinical approach to early T-cell precursor acute lymphoblastic leukemia.Blood research · 2026Review
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- Dasatinib reversibly disrupts T cell motility and activation in lymph nodes.Science advances · 2026Article
- Article
- Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.Cancer chemotherapy and pharmacology · 2026Article
- NUDT21 Drives T-Cell Acute Lymphoblastic Leukemia Through Dual Regulation of Alternative Polyadenylation and Transcriptional Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- [Clinical analysis of 7 cases of childhood acute lymphoblastic leukemia withZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- ELDA: real-time functional drug profiling in acute lymphoblastic leukemia.Frontiers in oncology · 2026Article
- A new sUSPect in T-ALL risk stratification.Blood advances · 2025Article
- ASS1 facilitates T-ALL progression via the arginine-mediated mTORC1/c-Myc signaling pathway.Scientific reports · 2025Article
- A single non-coding SNP in FPGS modulates folate drug efficacy in acute lymphoblastic leukemia: data-driven exploration and experimental validation.Molecular biomedicine · 2025Article
- Review
- Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia.Nature immunology · 2025Article
- Somatic mtDNA mutations at intermediate levels of heteroplasmy are a source of functional heterogeneity among primary leukemic cells.Science advances · 2025Article
- Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.Haematologica · 2025Review
- The identification of metabolites from gut microbiota in autism spectrum disorder via network pharmacology.Scientific reports · 2025Article
- Feeder Cell Detachment in Drug Response Profiling of Leukemia Cell Coculture Can Be Prevented by Conditioned Medium.Cancer medicine · 2025Article
- Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review.Discover oncology · 2025Article
- Promising Drugs Targeting Specific Mechanisms of Deregulation in T Cell Lineage Acute Lymphoblastic Leukemia.Oncology and therapy · 2025Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
47 authors at 9 institutions in 3 countries.
Yoshihiro Gocho *Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jingjing Liu *Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-8184-8382
Jianzhong Hu *Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Wentao YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Neekesh V DhariaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5048-067X
Jingliao ZhangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Hao ShiDepartment of Immunology,, St. Jude Children's Research Hospital, Memphis, TN, USA.
Guoqing DuDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
August JohnDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Ting-Nien LinDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jeremy HuntDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Xin HuangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Bensheng JuDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Lauren RowlandDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Lei ShiDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Dylan MaxwellDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Brandon SmartDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Kristine R CrewsDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-7558-558X
Wenjian YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Kohei HagiwaraDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Yingchi ZhangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Kathryn RobertsDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-7626-4043
Hong WangDepartments of Structural Biology and Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wendy StockUniversity of Chicago Medical Center, Chicago, IL, USA.
Bartholomew EisfelderUniversity of Chicago Medical Center, Chicago, IL, USA.
Elisabeth PaiettaMontefiore Medical Center, Bronx, NY, USA.
Scott NewmanDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Giovanni RotiDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Mark LitzowDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
John EastonDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jinghui ZhangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0003-3350-9682
Junmin PengDepartments of Structural Biology and Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0003-0472-7648
Hongbo ChiDepartment of Immunology,, St. Jude Children's Research Hospital, Memphis, TN, USA.
Stanley PoundsDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-9167-2114
Mary V RellingDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-3720-9591
Hiroto InabaDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0003-0605-7342
Xiaofan ZhuState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Steven KornblauDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5990-9548
Ching-Hon PuiDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0003-0303-5658
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9347-2212
David TeacheyDepartment of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-7373-8987
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-1871-1850
Kimberly StegmaierDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0218-7895
William E EvansDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-9333-5322
Jiyang YuDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA. jiyang.yu@stjude.org.ORCID http://orcid.org/0000-0003-3629-4330
Jun J YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. jun.yang@stjude.org.ORCID http://orcid.org/0000-0002-0770-9659
St. Jude Children's Research Hospital · USThe University of Texas MD Anderson Cancer Center · USBroad Institute · USChinese Academy of Medical Sciences & Peking Union Medical College · CNUniversity of Chicago Medical Center · USMayo Clinic in Arizona · USMontefiore Medical Center · USUniversity of Parma · ITUniversity of Pennsylvania · US
Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MCPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2015 to 2019
$15.1MPHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)R37CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1987 to 2014
$9.7MIntegrating Transforming Approaches to Identify and Target New Vulnerabilities in CancerR35CA210030 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2016 to 2022
$7.3MGenetics-guided Individualization of Thiopurine TherapyR01GM118578 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YANG, JUN J. · 2017 to 2020
$2.2MIntracellular and Intercellular Network Rewiring and Hidden Driver Inference from Single-Cell DataR01GM134382 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YU, JIYANG · 2019 to 2023
$1.7MNCI NIH HHS P30 CA021765NCI NIH HHS R35 CA210030NCI NIH HHS R37 CA036401NCI NIH HHS U10 CA180820NCI NIH HHS U24 CA196172NIGMS NIH HHS P50 GM115279NIGMS NIH HHS R01 GM118578NIGMS NIH HHS R01 GM134382
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy, and novel therapeutics are much needed. Profiling patient leukemia' drug sensitivities
Indexed as
Precursor T-Cell Lymphoblastic Leukemia-LymphomaCell Line, TumorDasatinibHumansNetwork PharmacologyProto-Oncogene Proteins c-bcl-2T-LymphocytesBCL2 protein, humanDasatinibProto-Oncogene Proteins c-bcl-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06855810ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.